Skip to main content

Cardiol Therapeutics Inc(CRDL-T)
TSX

Today's Change
Real-Time Last Update
Day Low2.05
Day High2.31
Open:2.05
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newsfile
Upcoming Meeting Dates - April 20, 2026
Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Newsfile
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
Newsfile
Cardiol Therapeutics Announces Year-End 2025 Update on Operations
Newsfile
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Newsfile
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Newsfile
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
Newsfile
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Newsfile
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Newsfile
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
PressReach
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Newsfile
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
Newsfile
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
Newsfile
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
Newsfile
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027
Newsfile
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
PressReach
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Newsfile
Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Newsfile
Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders
Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Newsfile
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT
Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Newsfile
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
Baystreet
Stocks in play: ardiol Therapeutics Inc.
Newsfile
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Newsfile
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Newsfile
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Profile

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.